Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00676052 · ClinicalTrials.gov registry record · Phase 2

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
576
Enrollment target
20
Study locations

NCT00676052 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 576 participants, below the 1,036-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00676052, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
576 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.

Conditions Studied

Pulmonary Disease, Chronic Obstructive

Interventions

  • DRUG GSK233705 12.5mcg
  • DRUG GSK233705 25mcg
  • DRUG GSK233705 50mcg
  • DRUG GSK233705 100mcg
  • DRUG GSK233705 200mcg

Study Locations (20)

California

  • GSK Investigational Site - Fountain Valley
  • GSK Investigational Site - Fullerton
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Riverside
  • GSK Investigational Site - Roseville
  • GSK Investigational Site - San Diego

Florida

  • GSK Investigational Site - Brandon
  • GSK Investigational Site - Panama City
  • GSK Investigational Site - South Miami

Louisiana

  • GSK Investigational Site - Lafayette
  • GSK Investigational Site - Sunset

South Carolina

  • GSK Investigational Site - Charleston
  • GSK Investigational Site - Greenville

Alabama

  • GSK Investigational Site - Jasper

Arizona

  • GSK Investigational Site - Glendale

Idaho

  • GSK Investigational Site - Coeur d'Alene

Kentucky

  • GSK Investigational Site - Madisonville

Trial Details

FieldValue
Enrollment Target 576 participants
Start Date 2008-05-16
Est. Completion 2008-12-22
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00676052

The ClinicalTrials.gov registry entry for NCT00676052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 576 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,036-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (44% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 5 interventions - of which GSK233705 12.5mcg is the first listed.

NCT00676052 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT00676052 about?

NCT00676052 is a clinical study titled "Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.

What is the current status of trial NCT00676052?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 576 participants. The study started on 2008-05-16. Estimated completion is 2008-12-22.

What conditions does trial NCT00676052 study?

This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.

What interventions are being tested in trial NCT00676052?

The interventions under investigation include: GSK233705 12.5mcg (DRUG), GSK233705 25mcg (DRUG), GSK233705 50mcg (DRUG), GSK233705 100mcg (DRUG), GSK233705 200mcg (DRUG).

Who is sponsoring clinical trial NCT00676052?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00676052 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Disease, Chronic Obstructive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pulmonary Disease, Chronic Obstructive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.